BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 31300450)

  • 1. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
    J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
    Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
    Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
    Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
    Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hallmarks of RET and Co-occuring Genomic Alterations in
    Adashek JJ; Desai AP; Andreev-Drakhlin AY; Roszik J; Cote GJ; Subbiah V
    Mol Cancer Ther; 2021 Oct; 20(10):1769-1776. PubMed ID: 34493590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
    Wu G; Guo L; Gu Y; Huang T; Liu M; Zou X; Yang B; Huang P; Wen C; Yi L; Liao W; Zhao D; Zhu J; Zhang X; Liu Y; Yin Y; Chen S
    J Cancer Res Clin Oncol; 2023 Mar; 149(3):1019-1028. PubMed ID: 35220468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RET fusions in solid tumors.
    Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
    Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
    Hicks JK; Saller J; Wang E; Boyle T; Gray JE
    Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
    Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
    Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer.
    Lindquist KE; Karlsson A; Levéen P; Brunnström H; Reuterswärd C; Holm K; Jönsson M; Annersten K; Rosengren F; Jirström K; Kosieradzki J; Ek L; Borg Å; Planck M; Jönsson G; Staaf J
    Oncotarget; 2017 May; 8(21):34796-34810. PubMed ID: 28415793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.
    Lira ME; Choi YL; Lim SM; Deng S; Huang D; Ozeck M; Han J; Jeong JY; Shim HS; Cho BC; Kim J; Ahn MJ; Mao M
    J Mol Diagn; 2014 Mar; 16(2):229-43. PubMed ID: 24418728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
    Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
    Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Utility of Cell-Free DNA for the Detection of
    McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
    Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
    [No Abstract]   [Full Text] [Related]  

  • 14. Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay.
    Hou H; Yang X; Zhang J; Zhang Z; Xu X; Zhang X; Zhang C; Liu D; Yan W; Zhou N; Zhu H; Qian Z; Li Z; Zhang X
    Sci Rep; 2017 Nov; 7(1):14605. PubMed ID: 29097733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KIF5B-RET fusion kinase promotes cell growth by multilevel activation of STAT3 in lung cancer.
    Qian Y; Chai S; Liang Z; Wang Y; Zhou Y; Xu X; Zhang C; Zhang M; Si J; Huang F; Huang Z; Hong W; Wang K
    Mol Cancer; 2014 Jul; 13():176. PubMed ID: 25047660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105.
    Drilon A; Fu S; Patel MR; Fakih M; Wang D; Olszanski AJ; Morgensztern D; Liu SV; Cho BC; Bazhenova L; Rodriguez CP; Doebele RC; Wozniak A; Reckamp KL; Seery T; Nikolinakos P; Hu Z; Oliver JW; Trone D; McArthur K; Patel R; Multani PS; Ahn MJ
    Cancer Discov; 2019 Mar; 9(3):384-395. PubMed ID: 30487236
    [No Abstract]   [Full Text] [Related]  

  • 17. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA.
    Supplee JG; Milan MSD; Lim LP; Potts KT; Sholl LM; Oxnard GR; Paweletz CP
    Lung Cancer; 2019 Aug; 134():96-99. PubMed ID: 31320002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
    Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
    Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selpercatinib monotherapy in a Chinese patient with RET fusion/ EGFR co-mutated nonsmall cell lung cancer from the Phase II LIBRETTO-321 study: a case report.
    Wu L; Cheng Y; Huang D; Sun Y; Zhou C; Zhou J; Guo Y; Shao J; Zhang W; Lu S
    Anticancer Drugs; 2023 Oct; 34(9):1058-1064. PubMed ID: 37265026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET rearrangements are actionable alterations in breast cancer.
    Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
    Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.